A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Réa, Delphine; J. Mauro, Michael; Boquimpani, Carla; Minami, Yosuke; Lomaia, Elza; Voloshin, Sergey; Turkina, Anna; Kim, Dong‐Wook; F. Apperley, Jane; Abdo, André; Fogliatto, Laura; Dong Hwan Kim, Dennis; le Coutre, Philipp; Saußele, Susanne; Annunziata, Mario; P. Hughes, Timothy; Chaudhri, Naeem; Sasaki, Koji; Chee, Lynette; García‐Gutiérrez, Valentín; E. Cortes, Jörge; Aimone, Paola; Allepuz, Alex; Quenet, Sara; Bédoucha, Véronique; Hochhaus, Andreas

doi:10.1182/blood.2020009984

Public

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Published in Blood • Aug 18, 2021

Authors:

Delphine Réa

Michael J. Mauro

Carla Boquimpani

Abstract

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inh...

Subject

Bosutinib

Medicine

Open label

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!